Our highlights of 2018

The start of the new year calls for some reflection. This is why we have compiled an overview of our highlights of 2018. We are proud of the results of our work for health for all. Have a look!

2018 was a year of new collaborations, media attention, joint letters, political support and enlarging our digital presence.


The year started with our successful event in the European Parliament in Brussels – ‘How long is the arm of Big Pharma?’. With attendees from the European Parliament, European Commission, and the European Medicines Agency (EMA), the event resulted in much media coverage as well as recommendations that were included in the approval of the budget of EMA by the European Parliament.


We also established the Health Workers For All Coalition, to strengthen civil society’s voice in calling for a stronger global health workforce. In September, on the invitation of the World Health Organization (WHO), we chaired a session at the WHO International Platform on Health Worker Mobility in Geneva.


Some other highlights were our country report on finance for the health workforce in Malawi (and the Lancet’s referral to our report!), the start of our new project ‘Aid for Trade’, our petition for a national plan for endocrine-disrupting chemicals (EDCs) in the Dutch Parliament, three thought-provoking Global Health Café editions, and the launch of our knowledge platform.


Wemos looks forward to a fruitful 2019 with successes like the past year’s. All for health for all.


Curious? Read about our highlights of 2018 here


Recent News items

This week: 72nd World Health Assembly


From May 20-28, the 72nd session of the World Health Assembly (WHA) will take place in Geneva, Switzerland. Each year, senior health officials from the World Health Organization’s (WHO) Member States gather there to discuss the WHO’s progress, new goals and global health agenda and challenges. Wemos will be present as well as a civil society organization and attend sessions on Financing for Health, the Global Action Plan for Healthy Lives and Well-being and Access to Medicines.

Continue reading

Overpriced drugs developed with tax money


Research shows major Dutch public investments in drug development


Overpriced, a report published today jointly by The Centre for Research on Multinational Corporation (SOMO) and Wemos, examines the extent of Dutch public funding of drug development, through donations, loans and/or investments. This funding occurs both directly by financing development of new medicines, and indirectly through investments made into biotech companies, but channelled through universities, public research bodies, and national and regional investment funds. The report reveals, however, that because no conditions are set on these investments, the Government loses its chance to curb subsequent high drug prices.

Continue reading